- Home
- RIGL vs LE Comparison
RIGL vs LE Comparison
Compare RIGL & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | LE |
|---|---|---|
| Founded | 1996 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 456.7M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | LE |
|---|---|---|
| Price | $43.32 | $14.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $43.20 | $20.00 |
| AVG Volume (30 Days) | ★ 506.3K | 205.3K |
| Earning Date | 11-04-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | 0.38 |
| Revenue | $282,076,000.00 | ★ $1,314,437,000.00 |
| Revenue This Year | $65.53 | $2.06 |
| Revenue Next Year | $0.22 | $2.44 |
| P/E Ratio | ★ $7.10 | $38.68 |
| Revenue Growth | ★ 79.13 | N/A |
| 52 Week Low | $15.50 | $7.65 |
| 52 Week High | $52.24 | $17.12 |
Technical Indicators
Market Signals| Indicator | RIGL | LE |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 42.27 |
| Support Level | $42.68 | $14.00 |
| Resistance Level | $44.85 | $14.63 |
| Average True Range (ATR) | 1.80 | 0.67 |
| MACD | -0.26 | -0.11 |
| Stochastic Oscillator | 63.51 | 36.51 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.